US pharmaceutical giant Eli Lilly and Company (NYSE: LLY) has reported its financial results for the third quarter of 2024, with total revenues increasing by 20% year-on-year (YOY) to USD 11.439 billion. The growth was propelled by volume increases from Mounjaro and Zepbound, as well as higher realized prices.
In the US market, revenues reached USD 7.81 billion, marking a 46% YOY increase, primarily due to volume growth from Mounjaro and Zepbound, partially offset by a 22% decrease in Trulicity (dulaglutide) sales. Internationally, revenues fell 12% to USD 3.63 billion, attributed to a 10% decrease in volume and the sale of rights for the olanzapine portfolio in Q3 2023. Excluding the olanzapine portfolio, revenues and volume outside the US increased by 33% and 36%, respectively, driven mainly by Mounjaro and Verzenio.
For Q3 2024, global revenues for Mounjaro (for type 2 diabetes) were USD 3.11 billion, and US revenues for Zepbound (for weight management) were USD 1.26 billion. Over the first three quarters, Mounjaro and Zepbound generated sales of USD 8 billion and USD 3 billion, respectively. Other product revenues included a 18% YOY increase in worldwide Taltz sales to USD 880 million, a 2% YOY decrease in worldwide Jardiance sales to USD 686 million, and a 35% increase in worldwide Humalog sales to USD 534.6 million.
In pipeline developments, Ebglyss received US approval for treating moderate-to-severe atopic dermatitis, and Kisunla was approved in Japan for early symptomatic Alzheimer’s disease. For the first three quarters, Lilly’s revenues amounted to USD 31.51 billion, up 27%. The company, increasing investment in manufacturing capacity for tirzepatide, updated its 2024 revenue guidance to between USD 45.4 billion and USD 46.0 billion.- Flcube.com
